Clinical Trials Browser

INDUSTRY × Has announcements × blinatumomab × Clear all

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3 Completed

111 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Phase 2 Completed

45 enrolled 24 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 3 Terminated

405 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01207388 2020-02-10

BLAST

Phase 2 Completed

116 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma